Acid reflux on semaglutide
Both labels count it, a few points above placebo: 5% against 3% on WEGOVY. What is less settled is whether the drug changes the plumbing, and two 2026 studies looked at that with different instruments and did not agree.1
On this page
What the labels count
| Reaction | WEGOVY 2.4 mg | OZEMPIC 0.5 mg and 1 mg |
|---|---|---|
| Gastroesophageal reflux disease | 5% against 3% | 1.9% and 1.5% against 0% |
| Dyspepsia (indigestion) | 9% against 3% | 3.5% and 2.7% against 1.9% |
| Gastritis | 4% against 1% | 0.8% and 0.4% against 0.8% |
| Eructation (burping) | 7% against under 1% | 2.7% and 1.1% against 0% |
WEGOVY prescribing information, Table 3 (revised 6/2026): 2.4 mg injection, N=2,116 against 1,261 on placebo. OZEMPIC prescribing information, section 6.1 (revised 5/2026), the reactions listed below its 5% threshold, given as placebo, 0.5 mg and 1 mg. Both read September 2026.
Read the gastritis row on the OZEMPIC side: 0.8% on the drug at one dose and 0.8% on placebo. Not everything reported around the stomach separates from placebo, and the labels print the ones that do not alongside the ones that do: the whole of WEGOVY’s table and the whole of OZEMPIC’s are set out row by row.2
What the labels say about emptying
One line explains why this subject comes up at all, and it appears on both labels as a drug-interaction warning rather than a side effect:
WEGOVY delays gastric emptying. May impact absorption of concomitantly administered oral medications.
The label raises that for the sake of other medicines you swallow, not for heartburn. The one place it treats slow emptying as a hazard in its own right is the warning about food still in the stomach at the start of anesthesia. Whether slower emptying also pushes acid the wrong way is the question the two studies below went at from opposite directions.
The reporting databases say one thing
A 2026 study in Gut and Liver pooled three national adverse-event reporting systems — the American FAERS, the Japanese JADER and Canada Vigilance — and compared GLP-1 drugs against a different diabetes drug class rather than against nothing. Across 260,417 GLP-1 reports it found a GERD signal in all three databases: a reporting odds ratio of 2.83 in FAERS, 4.76 in JADER and 2.91 in Canada Vigilance, with the strongest drug-specific signals for semaglutide.3
The measurement says another
The other 2026 study, in the Journal of Clinical Gastroenterology, did not count reports. It looked at 132 patients with type 2 diabetes who underwent high-resolution manometry, a test of how the esophagus actually moves, and compared those on a GLP-1 drug with those not. Semaglutide was the most common drug among the users. Most of them had a normal test, there was no significant difference in diagnoses between the groups, and among those who had formal reflux testing there was no difference in detected reflux disease either.4
It is a small, retrospective study and it says so. But it is measurement rather than report, and it did not find what the databases suggest.4
Holding both at once
The honest position is not to pick the study that sounds more alarming or more reassuring. What is established is that the labels count reflux and indigestion a few points above placebo, in trials that asked. What is unsettled is whether that reflects a change in how the esophagus works, and the two 2026 studies looked at different things: one at what people report, the other at what a pressure catheter measures.
The practical part is unchanged either way. Heartburn that is new, persistent, or waking you up is worth a conversation with the person who prescribed this, and what changes about eating is where the adjustments people make are described. If several stomach symptoms occur together, the side-effect duration guide separates trial timing from a personal recovery deadline.
Questions
Does semaglutide cause acid reflux?
Both labels report reflux above placebo in their trials, 5% against 3% on WEGOVY’s table, so it is counted as a reaction. Whether the drug changes esophageal function is less settled: a 2026 reporting-database study found a GERD signal strongest for semaglutide, and a 2026 manometry study of 132 patients found no difference in measured function or detected reflux.
Is heartburn worse at a higher dose?
The labels do not show that cleanly. On OZEMPIC’s list the reflux figures were 1.9% at 0.5 mg and 1.5% at 1 mg, which is the wrong direction for a dose effect, and WEGOVY’s table reports one rate at 2.4 mg rather than a series.2
Is this the delayed gastric emptying people mention?
Read next
Sources
A reference, not medical advice, and not a substitute for your prescriber or pharmacist. If you think you are having a medical emergency, call your local emergency number.